ARQT RSI Chart
Last 7 days
17.1%
Last 30 days
-10.4%
Last 90 days
-1.3%
Trailing 12 Months
-2.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 106.4M | 0 | 0 | 0 |
2023 | 17.7M | 31.6M | 45.6M | 59.6M |
2022 | 0 | 0 | 0 | 3.7M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 02, 2024 | matsuda masaru | sold | -43,828 | 8.7378 | -5,016 | see remark |
May 02, 2024 | burnett patrick | sold | -83,489 | 8.7378 | -9,555 | see remarks |
May 02, 2024 | watanabe todd franklin | sold | -120,433 | 8.7378 | -13,783 | see remarks |
May 02, 2024 | moore matthew richard | sold | -40,901 | 8.7378 | -4,681 | svp and chief business officer |
May 01, 2024 | moore matthew richard | acquired | - | - | 4,166 | svp and chief business officer |
Apr 10, 2024 | topper david joseph | acquired | - | - | 110,000 | chief financial officer |
Mar 04, 2024 | heron patrick j | bought | 199,994 | 9.5 | 21,052 | - |
Mar 04, 2024 | burnett patrick | sold | -53,181 | 11.1212 | -4,782 | see remarks |
Mar 04, 2024 | moore matthew richard | sold | -38,568 | 11.1212 | -3,468 | svp and chief business officer |
Mar 04, 2024 | matsuda masaru | sold | -41,815 | 11.1212 | -3,760 | see remark |
Which funds bought or sold ARQT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | VIMA LLC | sold off | -100 | -9,690 | - | -% |
May 17, 2024 | Ikarian Capital, LLC | new | - | 5,843,350 | 5,843,350 | 0.64% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.88 | 36,799 | 78,844 | -% |
May 16, 2024 | Colony Group, LLC | new | - | 558,000 | 558,000 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 32.96 | 1,597,400 | 2,116,140 | -% |
May 16, 2024 | COMERICA BANK | added | 276 | 3,069 | 3,360 | -% |
May 15, 2024 | J. Goldman & Co LP | added | 755 | 13,682,200 | 14,224,000 | 0.46% |
May 15, 2024 | Clearline Capital LP | new | - | 789,659 | 789,659 | 0.04% |
May 15, 2024 | Brevan Howard Capital Management LP | sold off | -100 | -166,158 | - | -% |
May 15, 2024 | Sio Capital Management, LLC | unchanged | - | 4,248,270 | 6,302,450 | 1.88% |
Unveiling Arcutis Biotherapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Arcutis Biotherapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Arcutis Biotherapeutics Inc News
Income Statement (Quarterly) | ||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 |
Revenue | 266.5% | 50.00 | 14.00 | 38.00 | 5.00 | 3.00 | 2.00 | 1.00 |
Cost Of Revenue | - | - | - | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 |
Costs and Expenses | - | 81.00 | - | - | - | 79.00 | - | - |
Operating Expenses | - | - | - | 75.00 | 72.00 | 79.00 | 71.00 | 105 |
S&GA Expenses | 12.6% | 55.00 | 49.00 | 48.00 | 46.00 | 43.00 | 37.00 | 35.00 |
R&D Expenses | -2.7% | 23.00 | 24.00 | 26.00 | 25.00 | 35.00 | 54.00 | 30.00 |
Interest Expenses | -3.6% | 7.00 | 8.00 | 8.00 | 7.00 | 7.00 | 7.00 | 5.00 |
Income Taxes | 2392.3% | 0.00 | 0.00 | 3.00 | - | - | - | - |
Net Income | 46.6% | -35.38 | -66.28 | -44.76 | -70.99 | -80.10 | -72.02 | -107 |
Net Income Margin | 53.5% | -2.04* | -4.40* | -5.87* | -10.45* | -18.52* | -84.50* | - |
Free Cashflow | 43.8% | -31.60 | -56.25 | -44.05 | -66.76 | -80.43 | -71.19 | -67.70 |
Balance Sheet | |||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Assets | 40.2% | 479 | 341 | 293 | 321 | 379 | 449 | 509 | 300 | 364 | 408 | 387 | 433 | 471 | 298 | 198 | 232 | 254 | 107 |
Current Assets | 41.7% | 468 | 330 | 282 | 309 | 368 | 437 | 497 | 295 | 359 | 403 | 382 | 428 | 466 | 293 | 194 | 228 | 254 | 106 |
Cash Equivalents | 113.5% | 191 | 89.00 | 107 | 105 | 81.00 | 55.00 | 83.00 | 63.00 | 71.00 | 98.00 | 53.00 | 91.00 | 290 | 67.00 | 46.00 | 172 | 191 | 63.00 |
Inventory | 0.9% | 13.00 | 13.00 | 14.00 | 10.00 | 9.00 | 8.00 | 4.00 | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -11.0% | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 0.4% | 254 | 253 | 246 | 240 | 240 | 240 | 238 | 105 | 110 | 110 | 24.00 | 18.00 | 20.00 | 28.00 | 25.00 | 23.00 | 13.00 | 6.00 |
Current Liabilities | 1.4% | 47.00 | 47.00 | 42.00 | 37.00 | 37.00 | 38.00 | 37.00 | 27.00 | 33.00 | 33.00 | 19.00 | 13.00 | 15.00 | 23.00 | 21.00 | 19.00 | 12.00 | 5.00 |
Long Term Debt | 0.5% | 203 | 202 | 201 | 200 | 199 | 198 | 197 | 73.00 | 73.00 | 72.00 | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 202 | 201 | 200 | 199 | 198 | 197 | 73.00 | 73.00 | 72.00 | - | - | - | - | - | - | - | - |
Shareholder's Equity | 153.7% | 225 | 89.00 | 47.00 | 81.00 | 140 | 210 | 271 | 195 | 254 | 298 | 363 | 414 | 451 | 271 | 173 | 209 | 242 | - |
Retained Earnings | -3.6% | -1,017 | -981 | -915 | -870 | -799 | -719 | -647 | -540 | -472 | -408 | -336 | -280 | -238 | -202 | -167 | -129 | -94.28 | -66.30 |
Additional Paid-In Capital | 16.0% | 1,242 | 1,071 | 963 | 952 | 940 | 930 | 920 | 737 | 727 | 706 | 700 | 695 | 689 | 473 | 341 | 339 | 336 | 1.00 |
Shares Outstanding | 19.3% | 116 | 97.00 | 62.00 | 62.00 | 61.00 | 61.00 | 53.00 | 51.00 | 51.00 | 49.00 | 50.00 | 50.00 | - | - | - | - | - | - |
Float | - | - | - | - | 487 | - | - | - | 878 | - | - | - | 1,082 | - | - | - | 620 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 43.8% | -31,603 | -56,244 | -43,984 | -66,485 | -80,344 | -71,065 | -67,695 | -61,980 | -56,975 | -51,709 | -40,884 | -35,831 | -46,203 | -32,571 | -33,691 | -25,761 | -21,010 | -16,797 | -10,722 | -8,243 | -7,074 |
Share Based Compensation | 14.5% | 10,030 | 8,757 | 9,999 | 10,578 | 9,479 | 9,264 | 8,789 | 8,096 | 6,533 | 5,686 | 5,363 | 4,340 | 8,503 | 2,643 | 2,261 | 2,049 | 990 | 455 | 154 | 139 | 76.00 |
Cashflow From Investing | 53.9% | -28,697 | -62,186 | 45,549 | 89,118 | 107,751 | 42,201 | -197,262 | 52,565 | 15,297 | 23,499 | 3,471 | -164,919 | 61,996 | -75,892 | -91,711 | 6,105 | -20,326 | -35,999 | 21,096 | -2,152 | -9,270 |
Cashflow From Financing | 62.9% | 161,764 | 99,289 | 867 | 1,067 | 100 | 962 | 284,989 | 1,131 | 14,716 | 72,881 | 63.00 | 1,188 | 207,815 | 129,380 | -437 | 309 | 168,893 | 92,955 | -20.00 | 168 | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Total revenues | $ 21,569 | $ 2,781 |
Other revenue | 28,000 | 0 |
Total revenues | 49,569 | 2,781 |
Operating expenses: | ||
Cost of sales | 3,256 | 783 |
Research and development | 23,141 | 35,345 |
Selling, general, and administrative | 54,794 | 42,918 |
Total operating expenses | 81,191 | 79,046 |
Loss from operations | (31,622) | (76,265) |
Other income (expense): | ||
Other income, net | 4,044 | 3,207 |
Interest expense | (7,480) | (7,042) |
Loss before income taxes | (35,058) | (80,100) |
Provision for income taxes | 324 | 0 |
Net loss | (35,382) | (80,100) |
Other comprehensive income (loss): | ||
Unrealized income (loss) on marketable securities | (116) | 724 |
Foreign currency translation adjustment | (21) | (52) |
Total other comprehensive income (loss) | (137) | 672 |
Comprehensive loss | $ (35,519) | $ (79,428) |
Per share information: | ||
Net loss per share, basic (in USD per share) | $ (0.32) | $ (1.31) |
Net loss per share, diluted (in USD per share) | $ (0.32) | $ (1.31) |
Weighted-average shares used in computing net loss per share, basic (in shares) | 111,048,525 | 61,169,089 |
Weighted-average shares used in computing net loss per share, diluted (in shares) | 111,048,525 | 61,169,089 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 190,097 | $ 88,398 |
Restricted cash | 617 | 925 |
Marketable securities | 213,769 | 183,463 |
Trade receivables, net | 37,154 | 25,807 |
Inventories | 13,247 | 13,134 |
Prepaid expenses and other current assets | 13,178 | 18,704 |
Total current assets | 468,062 | 330,431 |
Property, plant, and equipment, net | 1,369 | 1,539 |
Intangible assets, net | 6,250 | 6,438 |
Operating lease right-of-use asset | 2,264 | 2,361 |
Other assets | 596 | 596 |
Total assets | 478,541 | 341,365 |
Current liabilities: | ||
Accounts payable | 12,969 | 11,992 |
Accrued liabilities | 33,584 | 33,941 |
Operating lease liability | 756 | 735 |
Total current liabilities | 47,309 | 46,668 |
Operating lease liability, noncurrent | 3,181 | 3,382 |
Long-term debt, net | 202,803 | 201,799 |
Other long-term liabilities | 306 | 849 |
Total liabilities | 253,599 | 252,698 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 115,505,437 and 96,787,343 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 12 | 9 |
Additional paid-in capital | 1,242,349 | 1,070,558 |
Accumulated other comprehensive loss | (133) | 4 |
Accumulated deficit | (1,017,286) | (981,904) |
Total stockholders’ equity | 224,942 | 88,667 |
Total liabilities and stockholders’ equity | $ 478,541 | $ 341,365 |